Safety Profile of Paxlovid in the Treatment of COVID-19

CONCLUSION: This study indicates that the most common AEs reported with Paxlovid in post-marketing experience are consistent with the safety assessment of antiviral drugs. Even without emerging apparent safety concerns, the incidence of serious outcomes was unexpectedly high, and a few cases of potential new AEs occurred.PMID:38415446 | DOI:10.2174/0113816128280987240214103432
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Source Type: research